177 related articles for article (PubMed ID: 17031388)
41. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
[TBL] [Abstract][Full Text] [Related]
42. Critical illness myopathy serum fractions affect membrane excitability and intracellular calcium release in mammalian skeletal muscle.
Friedrich O; Hund E; Weber C; Hacke W; Fink RH
J Neurol; 2004 Jan; 251(1):53-65. PubMed ID: 14999490
[TBL] [Abstract][Full Text] [Related]
43. Calcineurin and heat shock protein 72 in functionally overloaded rat plantaris muscle.
Oishi Y; Ogata T; Ohira Y; Taniguchi K; Roy RR
Biochem Biophys Res Commun; 2005 May; 330(3):706-13. PubMed ID: 15809055
[TBL] [Abstract][Full Text] [Related]
44. Roles of exercise and pharmacokinetics in cerivastatin-induced skeletal muscle toxicity.
Seachrist JL; Loi CM; Evans MG; Criswell KA; Rothwell CE
Toxicol Sci; 2005 Dec; 88(2):551-61. PubMed ID: 16141437
[TBL] [Abstract][Full Text] [Related]
45. Mitochondria of trained skeletal muscle are protected from deleterious effects of statins.
Bouitbir J; Daussin F; Charles AL; Rasseneur L; Dufour S; Richard R; Piquard F; Geny B; Zoll J
Muscle Nerve; 2012 Sep; 46(3):367-73. PubMed ID: 22907227
[TBL] [Abstract][Full Text] [Related]
46. Attenuation of contractile dysfunction by atorvastatin after intestinal ischemia reperfusion injury in rats.
Ozacmak VH; Sayan H; Igdem AA; Cetin A; Ozacmak ID
Eur J Pharmacol; 2007 May; 562(1-2):138-47. PubMed ID: 17335801
[TBL] [Abstract][Full Text] [Related]
47. Use of an indirect effect model to describe the LDL cholesterol-lowering effect by statins in hypercholesterolaemic patients.
Faltaos DW; Urien S; Carreau V; Chauvenet M; Hulot JS; Giral P; Bruckert E; Lechat P
Fundam Clin Pharmacol; 2006 Jun; 20(3):321-30. PubMed ID: 16671968
[TBL] [Abstract][Full Text] [Related]
48. Comparison of excitability parameters and sodium channel behavior of fast- and slow-twitch rat skeletal muscles for the study of the effects of hindlimb suspension, a model of hypogravity.
Desaphy JF; Pierno S; Liantonio A; De Luca A; Leoty C; Conte Camerino D
J Gravit Physiol; 1998 Jul; 5(1):P77-8. PubMed ID: 11542373
[TBL] [Abstract][Full Text] [Related]
49. A systems biology strategy reveals biological pathways and plasma biomarker candidates for potentially toxic statin-induced changes in muscle.
Laaksonen R; Katajamaa M; Päivä H; Sysi-Aho M; Saarinen L; Junni P; Lütjohann D; Smet J; Van Coster R; Seppänen-Laakso T; Lehtimäki T; Soini J; Oresic M
PLoS One; 2006 Dec; 1(1):e97. PubMed ID: 17183729
[TBL] [Abstract][Full Text] [Related]
50. Cholesterol biosynthesis regulation and protein changes in rat liver following treatment with fluvastatin.
Steiner S; Gatlin CL; Lennon JJ; McGrath AM; Seonarain MD; Makusky AJ; Aponte AM; Esquer-Blasco R; Anderson NL
Toxicol Lett; 2001 Mar; 120(1-3):369-77. PubMed ID: 11323196
[TBL] [Abstract][Full Text] [Related]
51. Effects of fluvastatin and coenzyme Q10 on skeletal muscle in normo- and hypercholesterolaemic rats.
Vincze J; Jenes Á; Füzi M; Almássy J; Németh R; Szigeti G; Dienes B; Gaál Z; Szentesi P; Jóna I; Kertai P; Paragh G; Csernoch L
J Muscle Res Cell Motil; 2015 Jun; 36(3):263-74. PubMed ID: 25920381
[TBL] [Abstract][Full Text] [Related]
52. Statins and PPARalpha agonists induce myotoxicity in differentiated rat skeletal muscle cultures but do not exhibit synergy with co-treatment.
Johnson TE; Zhang X; Shi S; Umbenhauer DR
Toxicol Appl Pharmacol; 2005 Nov; 208(3):210-21. PubMed ID: 16239165
[TBL] [Abstract][Full Text] [Related]
53. Rosuvastatin safety: An experimental study of myotoxic effects and mitochondrial alterations in rats.
El-Ganainy SO; El-Mallah A; Abdallah D; Khattab MM; Mohy El-Din MM; El-Khatib AS
Toxicol Lett; 2017 Jan; 265():23-29. PubMed ID: 27815113
[TBL] [Abstract][Full Text] [Related]
54. Effects of HMG-CoA reductase inhibitors on excitation-contraction coupling of rat skeletal muscle.
Pierno S; De Luca A; Liantonio A; Camerino C; Conte Camerino D
Eur J Pharmacol; 1999 Jan; 364(1):43-8. PubMed ID: 9920183
[TBL] [Abstract][Full Text] [Related]
55. Fluvastatin, rhabdomyolysis, and myotoxicity.
Murinson BB; Maragakis NJ; Jacobson TA
Mayo Clin Proc; 2008 Nov; 83(11):1296; author reply 1297. PubMed ID: 18990330
[No Abstract] [Full Text] [Related]
56. Fluvastatin-induced alterations of skeletal muscle function in hypercholesterolaemic rats.
Füzi M; Palicz Z; Vincze J; Cseri J; Szombathy Z; Kovács I; Oláh A; Szentesi P; Kertai P; Paragh G; Csernoch L
J Muscle Res Cell Motil; 2012 Mar; 32(6):391-401. PubMed ID: 22068225
[TBL] [Abstract][Full Text] [Related]
57. Analysis of a Skeletal Muscle Injury and Drug Interactions in Lovastatin- and Fenofibrate-Coadministered Dogs.
Kawata R; Yokoi T
Int J Toxicol; 2019; 38(3):192-201. PubMed ID: 31113311
[TBL] [Abstract][Full Text] [Related]
58. Subchronic toxicity of atorvastatin, a hydroxymethylglutaryl-coenzyme A reductase inhibitor, in beagle dogs.
Walsh KM; Albassam MA; Clarke DE
Toxicol Pathol; 1996; 24(4):468-76. PubMed ID: 8864188
[TBL] [Abstract][Full Text] [Related]
59. Cerivastatin induces type-I fiber-, not type-II fiber-, predominant muscular toxicity in the young male F344 rats.
Obayashi H; Nezu Y; Yokota H; Kiyosawa N; Mori K; Maeda N; Tani Y; Manabe S; Sanbuissho A
J Toxicol Sci; 2011 Aug; 36(4):445-52. PubMed ID: 21804308
[TBL] [Abstract][Full Text] [Related]
60. Comparative toxicity of high doses of vastatins currently used by clinicians, in CD-1 male mice fed with a hypercholesterolemic diet.
Díaz-Zagoya JC; Asenjo-Barrón JC; Cárdenas-Vázquez R; Martínez F; Juárez-Oropeza MA
Life Sci; 1999; 65(9):947-56. PubMed ID: 10465354
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
